Company · Trial Tracker

Biogen and Stoke Therapeutics presented 4-year data from open-label extension studies of zorevunersen for Dravet syndrome at a medical conference, but this trial is not in Biogen's candidate list.

3 Sept 2026 · readout topline

Biogen and Stoke Therapeutics presented 4-year data from Phase 1/2a open-label extension studies of zorevunersen in Dravet syndrome, showing sustained seizure reduction and cognitive/behavioral improvements with standard-of-care anti-seizure medicines.

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

3 Sept 2026 · regulatory

Lecanemab subcutaneous formulation approved in China for early Alzheimer's disease; not matched to candidate trials (AHEAD 3-45, Clarity AD, and early lecanemab studies are not China regulatory approvals).

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

3 Sept 2026 · regulatory

Lecanemab subcutaneous formulation approved in China as an initiation treatment for early Alzheimer's disease, enabling at-home administration.

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

1 Sept 2026 · corporate other

Biogen and Stoke Therapeutics announced presentations of 4-year clinical data on zorevunersen for Dravet syndrome at a conference; the trial is not among Biogen's supplied candidate studies.

1 Sept 2026 · corporate other

Biogen and Stoke Therapeutics announced presentations of clinical data on zorevunersen for Dravet syndrome at the European Epilepsy Congress, but this trial is not in the supplied candidate list.

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

31 Aug 2026 · regulatory

Canada's Drug Agency issued a final positive reimbursement recommendation for lecanemab (LEQEMBI) in early Alzheimer's disease, supporting patient access through public coverage.

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

31 Aug 2026 · regulatory

Canada's drug agency issued a final positive recommendation for public reimbursement of lecanemab (LEQEMBI) in early Alzheimer's disease.

Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

27 Aug 2026 · corporate other

Biogen CEO to participate in a fireside chat at Morgan Stanley's healthcare conference on September 14, 2026.

Showing the 10 most recent · 16 older releases in the archive

We check every one of its trials daily and tell you what moved.

Status changeStatus moved to completedWas recruiting · always alerts
Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
New trialNew trial registered in your scopeFirst posted within 30 days
Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English

US registryClinicalTrials.gov

EU registryCTIS · Soon